Head of Dengvaxia study admits she has relative in Sanofi

Jamaine Punzalan, ABS-CBN News

<figure class="op-interactive"><iframe height="315" src="https://www.youtube.com/embed/RU7FdPYTNyk?enablejsapi=1" width="560"></iframe></figure><div class="iwantbar">Watch more in <a href="//www.iwantv.com.ph/">iWantv</a> or <a href="//tfc.tv/">TFC.tv</a></div><p>MANILA - An official of the Research Institute for Tropical Medicine (RITM) who led a clinical trial of the controversial dengue vaccine Dengvaxia admitted Monday that she has a relative that works for drug maker Sanofi Pasteur.</p><p>The RITM in 2014 said their clinical trial for Dengvaxia showed &quot;promising results,&quot; including a 56-percent reduction of dengue in 3,500 test subjects. Two years later, the Philippine government started administering the vaccine to thousands of public school children.</p><ul class="op-related-articles">	<li><a href="http://news.abs-cbn.com/news/12/11/17/officials-defied-experts-advice-in-pursuing-dengue-immunization-program">Officials defied experts&#x27; advice in pursuing dengue immunization program</a></li></ul><ul class="op-related-articles">	<li><a href="http://news.abs-cbn.com/focus/12/13/17/did-sanofi-who-ignore-warning-signals-on-dengue-vaccine">Did Sanofi, WHO ignore warning signals on dengue vaccine?</a></li></ul><p>The P3.5-billion project, however, was suspended last year after Sanofi disclosed that the vaccine could make the dengue worse if given to those who have not been infected with the mosquito-borne disease.</p><p>Dr. Rosario Capeding, principal investigator at the RITM, confirmed in a Senate hearing that Hazel Dy Tioco, director of clinical research operations at Sanofi-Asia Pacific, is her niece.<br/> <br/>Capeding rejected claims that her relationship with Dy Tioco marred the Dengvaxia trial study with conflict of interest.</p><p>&quot;In terms of conflict of interest regarding blood relations in clinical trial, the requirement for a clinical trial staff is with regards to the education, training,&quot; she said.</p><p>&quot;The conduct of clinical trial is regulated. There are independent clinical research organizations which monitor the conduct,&quot; she added.</p><p>Capeding said her niece was not involved with the procurement and licensing of Dengvaxia.</p><p>The 3,500 subject of the clinical trial, which was funded by Sanofi, remains &quot;alive and well&quot;, except for one who died in a vehicular accident, she said.</p><figure class="op-interactive"><iframe allowfullscreen="" frameBorder="0" height="315" src="https://www.youtube.com/embed/ylkNRyCiebc" width="560"></iframe></figure>

<p>An official of the Research Institute for Tropical Medicine (RITM) who led a clinical trial of the controversial dengue vaccine Dengvaxia admitted Monday that she has a relative that works for drug maker Sanofi Pasteur.</p><p> </p>

An official of the Research Institute for Tropical Medicine (RITM) who led a clinical trial of the controversial dengue vaccine Dengvaxia admitted Monday that she has a relative that works for drug maker Sanofi Pasteur.

Head of Dengvaxia study admits she has relative in Sanofi | ABS-CBN

Entertainment

News

Metro.Style

Sports

More

News

Head of Dengvaxia study admits she has relative in Sanofi

Head of Dengvaxia study admits she has relative in Sanofi

Jamaine Punzalan,

ABS-CBN News

Published Jan 22, 2018 02:43 PM PHT

|

Updated Jul 16, 2019 06:39 PM PHT

Read More:

DZMM

Dengvaxia

Sanofi

RITM

Rosario Capeding

dengue

dengue vaccine

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Advertise with Us

Privacy Policy

Terms of Service

© 2025 ABS-CBN Corporation. All Rights Reserved.